Brasília – Even after the House of Representatives approved an urgent processing request for the bill proposing to break the patents on Mounjaro and Zepbound, the legislative text is unlikely to reach plenary debate until after the second half of March as priority shifts to other agenda items. The proposal, which seeks a compulsory licensing mechanism for the tirzepatide-based drugs on public-interest grounds, had been fast-tracked in early February following broad support for urgent consideration.

The procedural delay comes amid political negotiations and competing legislative priorities in the House leadership, led by Hugo Motta, who is expected to defer floor time for the bill despite its urgency status. If the postponement materializes, the postponement could extend deliberations beyond the earliest procedural estimates, slowing momentum for a high-profile measure that has attracted industry scrutiny and public debate over intellectual property, drug pricing and access.

Source: Folha / Portal97FM